title: [11C]CHIBA-1001 as a novel PET ligand for alpha7 nicotinic receptors in the brain: a PET study in conscious monkeys.
abstract: BACKGROUND
  The alpha7 nicotinic acetylcholine receptors (nAChRs) play an important role in the pathophysiology of neuropsychiatric diseases such as schizophrenia and Alzheimer's disease. However, there are currently no suitable positron emission tomography (PET) radioligands for imaging alpha7 nAChRs in the intact human brain. Here we report the novel PET radioligand [11C]CHIBA-1001 for in vivo imaging of alpha7 nAChRs in the non-human primate brain.
  
  
  RESULTS
  A receptor binding assay showed that CHIBA-1001 was a highly selective ligand at alpha7 nAChRs. Using conscious monkeys, we found that the distribution of radioactivity in the monkey brain after intravenous administration of [11C]CHIBA-1001 was consistent with the regional distribution of alpha7 nAChRs in the monkey brain. The distribution of radioactivity in the brain regions after intravenous administration of [11C]CHIBA-1001 was blocked by pretreatment with the selective alpha7 nAChR agonist SSR180711 (5.0 mg/kg). However, the distribution of [11C]CHIBA-1001 was not altered by pretreatment with the selective alpha4beta2 nAChR agonist A85380 (1.0 mg/kg). Interestingly, the binding of [11C]CHIBA-1001 in the frontal cortex of the monkey brain was significantly decreased by subchronic administration of the N-methyl-D-aspartate (NMDA) receptor antagonist phencyclidine (0.3 mg/kg, twice a day for 13 days); which is a non-human primate model of schizophrenia.
  
  
  CONCLUSIONS
  The present findings suggest that [11C]CHIBA-1001 could be a novel useful PET ligand for in vivo study of the receptor occupancy and pathophysiology of alpha7 nAChRs in the intact brain of patients with neuropsychiatric diseases such as schizophrenia and Alzheimer's disease.
authors.affiliation: Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan. hashimoto@faculty.chiba-u.jp
authors.forename: Kenji
authors.initials: K
authors.lastname: Hashimoto
authors.forename: Shingo
authors.initials: S
authors.lastname: Nishiyama
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Ohba
authors.forename: Masaaki
authors.initials: M
authors.lastname: Matsuo
authors.forename: Tatsuhiko
authors.initials: T
authors.lastname: Kobashi
authors.forename: Makoto
authors.initials: M
authors.lastname: Takahagi
authors.forename: Masaomi
authors.initials: M
authors.lastname: Iyo
authors.forename: Takeru
authors.initials: T
authors.lastname: Kitashoji
authors.forename: Hideo
authors.initials: H
authors.lastname: Tsukada
mesh_terms: D000818:Animals; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D002038:Bungarotoxins / Q000494:pharmacology; D003243:Consciousness; D004952:Esters / Q000494:pharmacology*; D007700:Kinetics; D008253:Macaca mulatta; D008297:Male; D008956:Models, Chemical; D010622:Phencyclidine / Q000494:pharmacology; D049268:Positron-Emission Tomography / Q000295:instrumentation* / Q000379:methods*; D019275:Radiopharmaceuticals / Q000494:pharmacology*; D011978:Receptors, Nicotinic / Q000378:metabolism*; D064569:alpha7 Nicotinic Acetylcholine Receptor
chemical_list: D019086:Bridged Bicyclo Compounds, Heterocyclic; D002038:Bungarotoxins; C533046:CHIBA 1001; C579167:Chrna7 protein, human; D004952:Esters; D019275:Radiopharmaceuticals; D011978:Receptors, Nicotinic; C516833:SSR180711; D064569:alpha7 Nicotinic Acetylcholine Receptor; D010622:Phencyclidine
references.citation: Mol Neurobiol. 1999 Aug;20(1):1-16
references.pmid: 10595869
references.citation: Prog Neurobiol. 2000 May;61(1):75-111
references.pmid: 10759066
references.citation: Brain Res Mol Brain Res. 2000 Mar 29;76(2):385-8
references.pmid: 10762715
references.citation: Annu Rev Pharmacol Toxicol. 2000;40:431-58
references.pmid: 10836143
references.citation: Behav Brain Res. 2000 Aug;113(1-2):97-103
references.pmid: 10942036
references.citation: Behav Brain Res. 2000 Aug;113(1-2):143-57
references.pmid: 10942041
references.citation: Biol Psychiatry. 2001 Feb 1;49(3):175-84
references.pmid: 11230868
references.citation: Biol Psychiatry. 2001 Feb 1;49(3):200-10
references.pmid: 11230871
references.citation: J Chem Neuroanat. 2001 Jul;22(1-2):115-26
references.pmid: 11470559
references.citation: Am J Psychiatry. 2001 Aug;158(8):1319-21
references.pmid: 11481170
references.citation: Arch Gen Psychiatry. 2002 Dec;59(12):1085-96
references.pmid: 12470124
references.citation: J Comp Neurol. 2003 Jun 16;461(1):49-60
references.pmid: 12722104
references.citation: Biol Psychiatry. 2003 Dec 1;54(11):1222-33
references.pmid: 14643090
references.citation: Brain Res. 2004 Mar 5;999(2):193-202
references.pmid: 14759498
references.citation: Neuropsychopharmacology. 2004 Nov;29(11):2018-23
references.pmid: 15199373
references.citation: Arch Gen Psychiatry. 1990 Feb;47(2):181-8
references.pmid: 2405807
references.citation: J Cereb Blood Flow Metab. 1990 Sep;10(5):740-7
references.pmid: 2384545
references.citation: Brain Res. 1994 Nov 14;663(2):191-8
references.pmid: 7874501
references.citation: Neurosci Lett. 1994 Dec 5;182(2):279-82
references.pmid: 7715827
references.citation: Arch Gen Psychiatry. 2006 Jun;63(6):630-8
references.pmid: 16754836
references.citation: Eur J Neurosci. 2006 May;23(10):2604-10
references.pmid: 16817863
references.citation: Arch Gen Psychiatry. 2006 Aug;63(8):907-15
references.pmid: 16894067
references.citation: Trends Pharmacol Sci. 2006 Sep;27(9):482-91
references.pmid: 16876883
references.citation: CNS Drug Rev. 2006 Summer;12(2):100-12
references.pmid: 16958984
references.citation: Psychopharmacology (Berl). 2006 Nov;188(4):509-20
references.pmid: 16832659
references.citation: Curr Pharm Des. 2006;12(30):3877-900
references.pmid: 17073685
references.citation: Eur J Pharmacol. 2006 Dec 28;553(1-3):191-5
references.pmid: 17094961
references.citation: Neuropsychopharmacology. 2007 Jan;32(1):17-34
references.pmid: 16936709
references.citation: Neuropsychopharmacology. 2007 Jan;32(1):1-16
references.pmid: 17019409
references.citation: Annu Rev Pharmacol Toxicol. 2007;47:699-729
references.pmid: 17009926
references.citation: Biol Psychiatry. 2007 Mar 1;61(5):577-81
references.pmid: 16712806
references.citation: Biol Psychiatry. 2008 Jan 1;63(1):92-7
references.pmid: 17601496
references.citation: Br J Pharmacol. 2008 Mar;153(5):1054-61
references.pmid: 18157163
references.citation: Biol Psychiatry. 1995 Jul 1;38(1):22-33
references.pmid: 7548469
references.citation: Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11962-7
references.pmid: 8876245
references.citation: Neuropharmacology. 1996 Jun;35(6):725-34
references.pmid: 8887981
references.citation: Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):587-92
references.pmid: 9012828
references.citation: Pharmacol Biochem Behav. 1997 May-Jun;57(1-2):231-41
references.pmid: 9164577
references.citation: Harv Rev Psychiatry. 1994 Nov-Dec;2(4):179-92
references.pmid: 9384901
references.citation: Neuropsychopharmacology. 1999 Mar;20(3):201-25
references.pmid: 10063482
references.citation: Brain Res Mol Brain Res. 1999 Mar 20;66(1-2):94-103
references.pmid: 10095081
references.citation: J Nucl Med. 2005 Feb;46(2):240-7
references.pmid: 15695782
references.citation: Schizophr Res. 2005 Jul 1;76(1):67-72
references.pmid: 15927799
references.citation: Neuropsychopharmacology. 2005 Oct;30(10):1861-9
references.pmid: 15841110
references.citation: J Nucl Med. 2006 Feb;47(2):302-12
references.pmid: 16455637
references.citation: Curr Pharm Des. 2006;12(6):677-84
references.pmid: 16472157
references.citation: Psychopharmacology (Berl). 2006 Mar;184(3-4):523-39
references.pmid: 16220335